JP2021522812A - グリコフォリンａ抗原結合タンパク質 - Google Patents

グリコフォリンａ抗原結合タンパク質 Download PDF

Info

Publication number
JP2021522812A
JP2021522812A JP2020562704A JP2020562704A JP2021522812A JP 2021522812 A JP2021522812 A JP 2021522812A JP 2020562704 A JP2020562704 A JP 2020562704A JP 2020562704 A JP2020562704 A JP 2020562704A JP 2021522812 A JP2021522812 A JP 2021522812A
Authority
JP
Japan
Prior art keywords
antigen
seq
binding protein
tolerance
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020562704A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019215590A5 (https=
JP2021522812A5 (https=
Inventor
ステファン・コントス
ローズ・ジャスコル・ルイス
ジュリー・ミッシェル・シルバーマン
ジアン・リィ
グレゴリー・ポール・コンリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anokion SA
Original Assignee
Anokion SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anokion SA filed Critical Anokion SA
Publication of JP2021522812A publication Critical patent/JP2021522812A/ja
Publication of JPWO2019215590A5 publication Critical patent/JPWO2019215590A5/ja
Publication of JP2021522812A5 publication Critical patent/JP2021522812A5/ja
Priority to JP2024203619A priority Critical patent/JP2025028927A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020562704A 2018-05-07 2019-05-07 グリコフォリンａ抗原結合タンパク質 Pending JP2021522812A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024203619A JP2025028927A (ja) 2018-05-07 2024-11-22 グリコフォリンａ抗原結合タンパク質

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862668132P 2018-05-07 2018-05-07
US62/668,132 2018-05-07
US201962805849P 2019-02-14 2019-02-14
US62/805,849 2019-02-14
US201962829920P 2019-04-05 2019-04-05
US62/829,920 2019-04-05
PCT/IB2019/053705 WO2019215590A1 (en) 2018-05-07 2019-05-07 Glycophorin a antigen-binding proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024203619A Division JP2025028927A (ja) 2018-05-07 2024-11-22 グリコフォリンａ抗原結合タンパク質

Publications (3)

Publication Number Publication Date
JP2021522812A true JP2021522812A (ja) 2021-09-02
JPWO2019215590A5 JPWO2019215590A5 (https=) 2022-05-16
JP2021522812A5 JP2021522812A5 (https=) 2022-05-16

Family

ID=66998454

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020562704A Pending JP2021522812A (ja) 2018-05-07 2019-05-07 グリコフォリンａ抗原結合タンパク質
JP2024203619A Pending JP2025028927A (ja) 2018-05-07 2024-11-22 グリコフォリンａ抗原結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024203619A Pending JP2025028927A (ja) 2018-05-07 2024-11-22 グリコフォリンａ抗原結合タンパク質

Country Status (4)

Country Link
US (1) US20220153859A1 (https=)
EP (1) EP3790901A1 (https=)
JP (2) JP2021522812A (https=)
WO (1) WO2019215590A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2012021512A2 (en) 2010-08-10 2012-02-16 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
KR102717969B1 (ko) 2014-02-21 2024-10-15 에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) 글리코타겟팅 치료제
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
EA202092723A1 (ru) 2018-05-09 2021-04-09 Зе Юниверсити Оф Чикаго Композиции и способы, касающиеся иммунной толерантности
US20250381255A1 (en) * 2022-02-17 2025-12-18 Anokion Sa Anti-asgr1 polypeptides and methods of use for immune tolerance
WO2025027015A1 (en) * 2023-08-01 2025-02-06 Diamante Srl Composition and methods for treating multiple sclerosis
CN118388650B (zh) * 2024-06-28 2024-08-27 杭州赛基生物科技有限公司 一种抗CD235a单克隆抗体及其制备方法和应用
GB202412620D0 (en) * 2024-08-28 2024-10-09 Alivedx Suisse Sa Diagnosis of coeliac disease
CN119350500B (zh) * 2024-11-15 2026-02-27 浙江大学 抗CD235a单克隆抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752582A (en) * 1982-12-17 1988-06-21 The United States Of America As Represented By The United States Department Of Energy Monoclonal antibodies to human glycophorin A and cell lines for the production thereof
JP2003501629A (ja) * 1999-05-28 2003-01-14 ステムセル テクノロジース インコーポレーテッド 免疫ロゼットを用いる細胞分離法
JP2015508770A (ja) * 2012-02-15 2015-03-23 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517257B2 (en) * 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
WO2017015141A1 (en) * 2015-07-17 2017-01-26 President And Fellows Of Harvard College Humanized anti-glycophorin a antibodies and uses thereof
AR110079A1 (es) * 2016-11-16 2019-02-20 Bayer Healthcare Llc Factor viii direccionado a los glóbulos rojos y método para su uso
US12116417B2 (en) * 2017-11-14 2024-10-15 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4752582A (en) * 1982-12-17 1988-06-21 The United States Of America As Represented By The United States Department Of Energy Monoclonal antibodies to human glycophorin A and cell lines for the production thereof
JP2003501629A (ja) * 1999-05-28 2003-01-14 ステムセル テクノロジース インコーポレーテッド 免疫ロゼットを用いる細胞分離法
JP2015508770A (ja) * 2012-02-15 2015-03-23 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ（ウペエフエル）Ｅｃｏｌｅ Ｐｏｌｙｔｅｃｈｎｉｑｕｅ Ｆｅｄｅｒａｌｅ ｄｅ Ｌａｕｓａｎｎｅ （ＥＰＦＬ） 赤血球結合治療剤

Also Published As

Publication number Publication date
EP3790901A1 (en) 2021-03-17
WO2019215590A1 (en) 2019-11-14
US20220153859A1 (en) 2022-05-19
JP2025028927A (ja) 2025-03-05

Similar Documents

Publication Publication Date Title
JP2021522812A (ja) グリコフォリンａ抗原結合タンパク質
US20250145718A1 (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
JP6860618B2 (ja) 抗補体Ｃ１ｓ抗体とそれらの用途
JP4695133B2 (ja) 抗ミオスタチン抗体
RU2562114C2 (ru) Антитела против ингибитора метаболического пути тканевого фактора
ES2647823T3 (es) Anticuerpos anti-CD100 y métodos de uso de los mismos
WO2020011275A1 (zh) 一种sema4d抗体及其制备方法和应用
CN105492462B (zh) 凝集素样氧化的ldl受体1抗体和使用方法
WO2021031716A1 (zh) 抗pd-l1单域抗体
TR201815563T4 (tr) Anti-alfa sinüklein bağlayıcı moleküller.
TW201041594A (en) Compositions and methods for increasing muscle growth
RS55571B1 (sr) Anti-c5a vezujuće grupe sa visokom blokirajućom aktivnosti
JP2021519305A (ja) 肝臓およびリンパ節の類洞内皮細胞Ｃ型レクチン（ＬＳＥＣｔｉｎ）を標的とするための方法および組成物
WO2020119728A1 (zh) 抗人白细胞介素5(il-5)单克隆抗体及其应用
JP2021515542A (ja) Ｐｄ１結合剤
EA026375B1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
US12252541B2 (en) Anti-BCMA antibody and use thereof
JP6277126B2 (ja) ホスホリルコリン（ｐｃ）および／またはｐｃコンジュゲートに結合する抗体
TW201333034A (zh) 新穎抗人類ｃｔｇｆ抗體
JPWO2013001819A1 (ja) 可溶性インテグリンα４変異体
US20240174744A1 (en) Methods of treatment using protein binders to irhom2 epitopes
CN112375146B (zh) 检测Anti-CD19 CAR表达水平的抗独特性抗体及其应用
WO2022136685A1 (en) Antibody compositions for treatment of corona virus infection
JP7676356B2 (ja) 新規ｂｓｓｌ抗体
WO2022141378A1 (zh) 一种抗pd-1的单域抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220506

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220506

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240321

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240424

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240723